This year, legislation to establish a pilot program to study the clinical use of psilocybin is pending before the General Assembly.
HB 5396 creates psilocybin and MDMA treatment centers in Connecticut, pending approval of the drugs by the federal FDA under its expanded access program for investigational new drugs.
The bill does not legalize psychedelics, instead establishing a Department of Mental Health and Addiction Services pilot program for treatment of qualified patients—Connecticut residents who are veterans, retired first responders, healthcare workers, or those who come from a historically underserved community and suffer from a serious mental health disorder—at “approved treatment sites.”
Comments